Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for
tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who
have advanced or metastatic sarcoma.